**Supplementary Table 1.** **ALT, APRI, and FIB-4 of patients discontinuing treatment at the BL, EOT, and EOF.**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Index** | **BL** | **EOT** | **EOF** | ***p\**** | ***p#*** | ***p¶*** |
| ALT, U/L |  |  |  |  |  |  |
| Discontinued, *n* = 40 | 22 (18, 28) | 25 (19, 31) | 25 (21, 29) | 0.019 | 0.040 | 0.977 |
| Relapsed, *n* = 32 | 22 (18, 28) | 25 (20, 30) | 25 (21, 28) | 0.006 | 0.031 | 0.550 |
| Nonrelapsed, *n* = 7 | 25 (22, 30) | 28 (18, 31) | 28 (14, 37) | 0.625 | 1.000 | 0.563 |
| APRI |  |  |  |  |  |  |
| Discontinued, *n* = 40 | 0.31 (0.24, 0.46) | 0.31 (0.25, 0.48) | 0.67 (0.54, 0.86) | 0.627 | < 0.001 | < 0.001 |
| Relapsed, *n* = 32 | 0.28 (0,23, 0.42) | 0.29 (0.24, 0.43) | 0.66 (0.54, 0.84) | 0.934 | < 0.001 | < 0.001 |
| Nonrelapsed, *n* = 7 | 0.54 (0.25, 0.57) | 0.55 (0.27, 0.63) | 0.45 (0.78, 1.05) | 0.297 | 0.016 | 0.031 |
| FIB-4 |  |  |  |  |  |  |
| Discontinued, *n* = 40 | 0.98 (0.81, 1.57) | 1.11 (0.79, 1.75) | 2.34 (1.74, 3.31) | 0.572 | < 0.001 | < 0.001 |
| Relapsed, *n* = 32 | 0.94 (0.67, 1.42) | 0.93 (0.75, 1.53) | 2.24 (1.70, 3.22) | 0.651 | < 0.001 | < 0.001 |
| Nonrelapsed, *n* = 7 | 1.62 (0.89, 1.82) | 1.87 (1.06, 2.22) | 3.08 (2.44, 3.85) | 0.156 | 0.031 | 0.031 |

Data are presented as median (IQR), unless otherwise specified. *\*p*, BL vs. EOT; *#p*, BL vs. EOF; *¶p*, EOT vs. EOF. ALT, alanine aminotransferase; APRI, aspartate aminotransferase to platelet ratio index; BL, baseline; EOT, end of treatment; EOF, end of follow-up; FIB-4, fibrosis-4 index.